

## State of Oklahoma SoonerCare

## Stivarga® (Regorafenib) Prior Authorization Form

Drug Information   Pharmacy billing (NDC:	Member Name:	Date of Birth:	Member ID#:	
Dosing Regimen:   Billing Provider Information	Drug Information			
Pharmacy NPI:	Pharmacy billing (NDC:) Start Date (or date of next dose):			
Pharmacy NPI:	Dose:Dosing Regimen:			
Prescriber Information  Prescriber NPI:	Billing Provider Information			
Prescriber NPI:	Pharmacy NPI:	harmacy NPI:Pharmacy Name:		
Prescriber NPI:	Pharmacy Phone: Pharmacy Fax:			
Prescriber Phone:	Prescriber Information			
For Initial Authorization:  1. Please indicate the diagnosis and information:  Colorectal Cancer  A. Is the disease metastatic, recurrent, or unresectable? Yes No  B. Was the member previously treated with a fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy? Yes No  C. Was the member previously treated with an anti-vascular endothelial growth factor (VEGF) therapy? Yes No  D. Is disease RAS wild-type disease? Yes No  i. If yes, was the member previously treated with an anti-epidermal growth factor receptor (EGFR) therapy? Yes No  Gastrointestinal Stromal Tumor  A. Is the disease locally advanced unresectable or metastatic? Yes No  B. Was the member previously treated with imatinib and sunitinib? Yes No  Hepatocellular Carcinoma  A. Was the member previously treated with sorafenib? Yes No  Osteosarcoma  A. Is disease relapsed or refractory? Yes No  B. Will regorafenib be used in the second line or greater setting? Yes No  Other:  For Continued Authorization:  1. Date of last dose:  2. Does the member have any evidence of progressive disease while on regorafenib ? Yes No  3. Has the member experienced any adverse drug reactions related to regorafenib therapy? Yes No	Prescriber NPI: Prescriber Name:			
1. Please indicate the diagnosis and information:  Colorectal Cancer  A. Is the disease metastatic, recurrent, or unresectable? Yes No  B. Was the member previously treated with a fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy? Yes No  C. Was the member previously treated with an anti-vascular endothelial growth factor (VEGF) therapy? Yes No  D. Is disease RAS wild-type disease? Yes No  i. If yes, was the member previously treated with an anti-epidermal growth factor receptor (EGFR) therapy? Yes No  Gastrointestinal Stromal Tumor  A. Is the disease locally advanced unresectable or metastatic? Yes No  B. Was the member previously treated with imatinib and sunitinib? Yes No  Hepatocellular Carcinoma  A. Was the member previously treated with sorafenib? Yes No  Osteosarcoma  A. Is disease relapsed or refractory? Yes No  B. Will regorafenib be used in the second line or greater setting? Yes No  Other:  For Continued Authorization:  1. Date of last dose:  2. Does the member have any evidence of progressive disease while on regorafenib? Yes No  3. Has the member experienced any adverse drug reactions related to regorafenib therapy? Yes No	Prescriber Phone: Pr	escriber Fax:	Specialty:	
1. Please indicate the diagnosis and information:  Colorectal Cancer  A. Is the disease metastatic, recurrent, or unresectable? Yes No B. Was the member previously treated with a fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy? Yes No C. Was the member previously treated with an anti-vascular endothelial growth factor (VEGF) therapy? Yes No No C. Was the member previously treated with an anti-epidermal growth factor receptor (EGFR) therapy? Yes No C. If yes, was the member previously treated with an anti-epidermal growth factor receptor (EGFR) therapy? Yes No C. Was the disease locally advanced unresectable or metastatic? Yes No C. B. Was the member previously treated with imatinib and sunitinib? Yes No C. Will regorafenib be used in the second line or greater setting? Yes No C. Will regorafenib be used as a single agent? Yes No C. Will regorafenib be used as a single agent? Yes No C. Will regorafenib the used and the second line or greater setting? Yes No C. Will regorafenib the used and the second line or greater setting? Yes No C. Will regorafenib the used and so single agent? Yes No C. Will regorafenib the used and so single agent? Yes No C. Will regorafenib the used and yevidence of progressive disease while on regorafenib? Yes No C. No C. Does the member have any evidence of progressive disease while on regorafenib therapy? Yes No C. With the progressive disease while on regorafenib therapy? Yes No C. With the progressive disease while on regorafenib therapy? Yes No C. With the progressive disease while on regorafenib therapy? Yes No C. With the progressive disease while on regorafenib therapy? Yes No C. With the progressive disease while on regorafenib therapy? Yes No C. With the progressive disease while on regorafenib therapy? Yes No C. With the progressive disease while on regorafenib therapy? Yes No C. With the progressive disease while on regorafenib therapy? Yes No C. With the progressive disease while on regorafenib therapy? Yes No C. With the progressive disease while on regora	<b>Criteria</b>			
Prescriber Signature: Date:  I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my	A. Is the disease metastatic, recurrent, or unresectable? Yes No B. Was the member previously treated with a fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy? Yes No C. Was the member previously treated with an anti-vascular endothelial growth factor (VEGF) therapy? Yes No D. Is disease RAS wild-type disease? Yes No C. If yes, was the member previously treated with an anti-epidermal growth factor receptor (EGFR) therapy? Yes No C. Is the disease locally advanced unresectable or metastatic? Yes No B. Was the member previously treated with imatinib and sunitinib? Yes No C. Hepatocellular Carcinoma  A. Is disease relapsed or refractory? Yes No B. Will regorafenib be used in the second line or greater setting? Yes No C. Will regorafenib be used as a single agent? Yes No C. Will regorafenib be used as a single agent? Yes No C. Will regorafenib de used in the second line or greater setting? Yes No C. Does the member have any evidence of progressive disease while on regorafenib? Yes No S. Has the member experienced any adverse drug reactions related to regorafenib therapy? Yes No If yes, please specify adverse reactions:			

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts.

All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.

## **CONFIDENTIALITY NOTICE**

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 218 8/21/2023